What is the most common cause of fetal goiter, its associated risks, recommended management, and appropriate diagnostic tests?

Fetal Goiter: Causes, Risks, Management, and Diagnostic Testing

Most Common Cause

The most common cause of fetal goiter is maternal Graves' disease with transplacental passage of thyroid-stimulating antibodies (TRAb), though iatrogenic fetal hypothyroidism from maternal antithyroid drug (ATD) overtreatment is also a significant cause 1. Fetal goiter occurs in approximately 1 in 5,000 births and is predominantly associated with maternal thyroid disease 2.

Key Etiologies to Consider:

• Maternal Graves' disease (current or past history, even after radioiodine ablation or thyroidectomy) with elevated TRAb causing fetal hyperthyroidism 1
• Maternal ATD overtreatment causing iatrogenic fetal hypothyroidism 1
• Dyshormonogenetic goiter (fetal thyroid hormone synthesis defects) in euthyroid mothers 3, 4, 5
• Inadvertent maternal radioiodine exposure after 12 weeks gestation causing fetal thyroid destruction 1

Associated Risks

Fetal goiter carries substantial morbidity and mortality risks, including intrauterine growth restriction, preterm delivery, fetal hydrops, cardiac failure, and fetal death 1.

Specific Complications:

For fetal hyperthyroidism:

• Fetal tachycardia
• Intrauterine growth restriction
• Advanced bone age
• Fetal hydrops
• Preterm delivery
• Fetal death 1

For fetal hypothyroidism:

• Polyhydramnios 3, 4
• Airway obstruction from goiter mass effect 6
• Neurodevelopmental impairment if untreated 3, 4
• Respiratory distress at delivery 6

Critical pitfall: Even without obvious sonographic signs of tracheoesophageal compression, life-threatening airway obstruction can occur at delivery 6.

Diagnostic Testing

Measure maternal TRAb by 22 weeks gestation in all women with current Graves' disease, history of Graves' disease treated with radioiodine or thyroidectomy, previous neonate with Graves' disease, or previously elevated TRAb 1.

Algorithmic Diagnostic Approach:

Step 1 - Maternal Assessment:

• Maternal TSH, free T4, T3 levels
• TRAb levels (critical for determining fetal hyperthyroidism risk) 1
• Document current ATD use and dosing

Step 2 - Fetal Ultrasound Surveillance:

• Begin at 18-22 weeks (fetal anatomy scan) in at-risk mothers 1
• Repeat every 4-6 weeks if TRAb elevated ≥2-3 fold normal or mother on ATD 1
• Assess for:
  • Thyroid enlargement/goiter
  • Fetal heart rate (tachycardia >160-170 bpm suggests hyperthyroidism)
  • Growth restriction
  • Hydrops
  • Advanced bone age
  • Cardiac function 1
  • Tracheoesophageal patency (though this can be falsely reassuring) 6

Step 3 - Cordocentesis (Selective Use):

• Only perform if diagnosis uncertain from clinical and ultrasound data AND the information would change management 1
• Measure fetal TSH and free T4 6, 3, 4
• Recognize this is an invasive procedure with inherent risks

Key diagnostic principle: TRAb levels >3 times upper normal limit typically indicate risk for fetal hyperthyroidism 1.

Management

If fetal hyperthyroidism is diagnosed and endangers the pregnancy, treat with maternal MMI or PTU at the minimum effective dose, with frequent clinical, laboratory, and ultrasound monitoring 1.

Management Algorithm by Etiology:

For Fetal Hyperthyroidism (from maternal TRAb):

• Maternal ATD therapy: PTU in first trimester (due to MMI embryopathy risk), switch to MMI in second trimester (due to PTU hepatotoxicity) 1
• Target maternal free T4 at upper limit of normal (1.5-2× ULN) to avoid fetal hypothyroidism while treating hyperthyroidism 7
• Avoid iodine supplementation 7
• Serial ultrasound every 4-6 weeks 1

For Fetal Hypothyroidism (from ATD overtreatment or dyshormonogenesis):

• Reduce or discontinue maternal ATD if iatrogenic 1
• Intra-amniotic levothyroxine injections for dyshormonogenetic goiter with significant size or polyhydramnios 3, 4
  • Weekly injections have shown goiter reduction and improved outcomes 3, 4
  • Monitor for reduction in goiter size and amniotic fluid volume 4

Delivery Planning:

• Planned cesarean section if large goiter present (risk of airway obstruction) 6, 2
• Multidisciplinary team including maternal-fetal medicine, neonatology, pediatric endocrinology, anesthesia, and potentially ENT/pediatric surgery 6
• Consider EXIT (ex utero intrapartum treatment) procedure for massive goiters with anticipated airway compromise 6, 5
• Timing: Aim for term delivery unless maternal or fetal indications necessitate earlier delivery 2
• Second trimester (if surgery needed) is safest window for maternal thyroidectomy, though surgery should not be contraindicated at any stage if maternal prognosis at risk 7

Critical management pitfall: Ultrasound assessment of tracheoesophageal patency may be falsely reassuring—always prepare for potential airway emergency at delivery 6.

Postpartum:

• Immediate neonatal thyroid function testing
• Pediatric endocrinology follow-up
• Levothyroxine replacement for confirmed neonatal hypothyroidism 3, 4

Important caveat: Despite optimal management in specialized centers, prognosis remains guarded with significant mortality risk, particularly with large goiters causing cardiac decompensation or airway obstruction 6.